The Clinical Research Contracts (CRC) team supports UMB investigators by negotiating agreements required to initiate and manage commercially sponsored clinical trials. CRC works closely with Clinical Billing Analysis to ensure contracts align with approved budgets and billing requirements.
Clinical Research Contracts
CRC Services
-
Confidential Disclosure Agreements (CDAs)
Negotiates CDAs with commercial partners to allow the review of confidential clinical trial information, including sponsor-initiated trial protocols.
-
Clinical Trial Agreements (CTAs)
Negotiates Clinical Trial Agreements and amendments to CTAs with commercial sponsors.
-
Coordination with Clinical Billing Analysis
Coordinates CTA negotiation and execution to ensure alignment with clinical billing and budget requirements
Important: CRC does not negotiate Clinical Trial Agreements funded by government agencies, foundations, or other nonprofit organizations. These agreements are handled by ORD’s Sponsored Programs Administration (SPA).
Contact:
Amshu Siddalingaswamy
Director, Resource Management and Business Operations
Submit a Request
To submit a Confidential Disclosure Agreement (CDA) or Clinical Trial Agreement (CTA) request:
- Use the Confidential Disclosure Agreement (CDA) or CTA Request Form, or
- Log in to the myUMB Portal and select UMBiz from the Administrative Systems menu.
Confidential Disclosure Agreements (CDAs)
Confidential Disclosure Agreements (CDAs)—also known as Confidentiality Agreements, Non-Disclosure Agreements (NDAs), or Secrecy Agreements—are legal agreements used to protect confidential information exchanged between parties. CDAs may be:
- Unilateral, where one party discloses information, or
- Bilateral, where both parties exchange confidential information.
CDAs establish legal and procedural requirements for how confidential information, intellectual property, and proprietary know-how may be disclosed, used, and protected.
A CDA should be executed before confidential information is shared, including in the following situations:
- Before sharing unpublished research results with a company
- Before disclosing an invention to a potential licensee
- Before a clinical trial sponsor releases a study protocol for principal investigator review
Because UMB is typically named as a legal party to the agreement, CDAs are signed on behalf of the University by an Office of Research and Development–authorized official.
Need help?
Contact Amshu Siddalingaswamy for additional information or assistance.
Contact
Office of Research and Development | ORD
620 W. Lexington St.
Fourth Floor
Baltimore, MD 21201